GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » Beneish M-Score

Augmedix (Augmedix) Beneish M-Score : -2.45 (As of Apr. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Augmedix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Augmedix's Beneish M-Score or its related term are showing as below:

AUGX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.45   Med: -2.18   Max: -1.3
Current: -2.45

During the past 5 years, the highest Beneish M-Score of Augmedix was -1.30. The lowest was -2.45. And the median was -2.18.


Augmedix Beneish M-Score Historical Data

The historical data trend for Augmedix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix Beneish M-Score Chart

Augmedix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -1.30 -2.18 -2.45

Augmedix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -0.96 -1.83 -2.02 -2.45

Competitive Comparison of Augmedix's Beneish M-Score

For the Health Information Services subindustry, Augmedix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Augmedix's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Augmedix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Augmedix's Beneish M-Score falls into.



Augmedix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Augmedix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9303+0.528 * 0.94+0.404 * 0.4932+0.892 * 1.4501+0.115 * 1.9621
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7674+4.679 * -0.069343-0.327 * 0.6843
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $8.57 Mil.
Revenue was 12.68 + 11.767 + 10.78 + 9.628 = $44.86 Mil.
Gross Profit was 6.245 + 5.83 + 5.065 + 4.386 = $21.53 Mil.
Total Current Assets was $56.82 Mil.
Total Assets was $66.71 Mil.
Property, Plant and Equipment(Net PPE) was $8.96 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.10 Mil.
Selling, General, & Admin. Expense(SGA) was $29.13 Mil.
Total Current Liabilities was $23.62 Mil.
Long-Term Debt & Capital Lease Obligation was $19.35 Mil.
Net Income was -4.492 + -4.407 + -5.033 + -5.239 = $-19.17 Mil.
Non Operating Income was 0.094 + 0.434 + 0.234 + 0.134 = $0.90 Mil.
Cash Flow from Operations was -0.973 + -2.293 + -5.954 + -6.221 = $-15.44 Mil.
Total Receivables was $6.35 Mil.
Revenue was 8.751 + 7.864 + 7.333 + 6.985 = $30.93 Mil.
Gross Profit was 4.049 + 3.59 + 3.202 + 3.113 = $13.95 Mil.
Total Current Assets was $29.55 Mil.
Total Assets was $33.64 Mil.
Property, Plant and Equipment(Net PPE) was $3.14 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.86 Mil.
Selling, General, & Admin. Expense(SGA) was $26.18 Mil.
Total Current Liabilities was $19.31 Mil.
Long-Term Debt & Capital Lease Obligation was $12.35 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.572 / 44.855) / (6.354 / 30.933)
=0.191105 / 0.205412
=0.9303

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13.954 / 30.933) / (21.526 / 44.855)
=0.451104 / 0.479902
=0.94

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (56.823 + 8.959) / 66.712) / (1 - (29.55 + 3.14) / 33.641)
=0.013941 / 0.028269
=0.4932

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=44.855 / 30.933
=1.4501

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.856 / (0.856 + 3.14)) / (1.098 / (1.098 + 8.959))
=0.214214 / 0.109178
=1.9621

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(29.129 / 44.855) / (26.176 / 30.933)
=0.649404 / 0.846216
=0.7674

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((19.352 + 23.618) / 66.712) / ((12.352 + 19.314) / 33.641)
=0.644112 / 0.941292
=0.6843

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-19.171 - 0.896 - -15.441) / 66.712
=-0.069343

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Augmedix has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.


Augmedix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Augmedix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Augmedix (Augmedix) Business Description

Traded in Other Exchanges
N/A
Address
111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
Executives
Paul Ginocchio officer: Chief Financial Officer C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor director 5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner director C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly director C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc director, 10 percent owner ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo director 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins officer: Chief Revenue Officer C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber officer: CHIEF OPERATING OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil officer: CHIEF STRATEGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris director, officer: PRESIDENT, CEO, AND SECRETARY C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee officer: CHIEF TECHNOLOGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw director 4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian director, 10 percent owner C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103